In part 7 of this Exclusive Interview, Scott Abbott shares what's next on the V-Go front in a conversation with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.

In the conclusion of this Exclusive Interview, Scott Abbott talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California, about the patient response to the V-Go system.

Too often when we see patients we arbitrarily give them a goal A1c. Most of us don’t make every person strive for 5.7, but we sometimes forget to find out what the patient really thinks they can accomplish. This week we combined information from Dr. Karl Nadolsky and our Medical Editor to …

A disaster can be considered many different things to different people. For some it could mean developing type 2 diabetes rather than preventing or delaying it. If you watch our expert video series you will hear our Publisher ask many of our experts, “Whether or not you have diabetes, what would you like your A1C to be?” As our expert, Dr. Karl Nadolsky said, he’d like his to be in the normal range, ~ 5%. This is not unusual for us as health care providers to want and work towards a normal A1C, that is, depending on age, and risk for complications of hypoglycemia.

Dr. Minisha Sood is an endocrinologist, assistant professor at Hofstra School of Medicine and a 2017 recipient of the Castle Connolly Exceptional Women in Medicine Award. Her areas of expertise include diabetes, thyroid disorders, obesity, and polycystic ovary syndrome. Also the 2017 recipient of the Castle Connolly Exceptional Women in Medicine Award, Dr. Caroline Messer is a clinical assistant professor at the Mount Sinai School of Medicine and an assistant professor at Hofstra School of Medicine. Dr. Messer is actively engaged in clinical research and is a frequent guest lecturer to other physicians on topics such as thyroid disease, osteoporosis, polycystic ovary syndrome, and diabetes.

In this week's Homerun Slides, Dr. Claude Lardinois focuses on the importance of albuminuria as it relates to chronic kidney disease in people with type 2 diabetes.

The wonders of lactate: Very recently, our laboratory has made a major improvement in the use of the minimal model to assess insulin sensitivity and evaluate its importance in metabolic control. During the FSIGT, as it is practiced, there is initially a large increase in glucose concentration, due to the glucose injection, there is an endogenous finite insulin response in normal individuals, and the insulin is then increased again at 20 min after the exogenous insulin injection. We considered the question of the fate of the injected glucose before the secondary insulin injection. In the absence of a large increase in insulin, much of the glucose is disposed by an insulin-independent mechanism, a process we termed “glucose effectiveness.”

Diabetes in Control Publisher Steve Freed talks with two of the presenters at the AACE 26th Annual Scientific & Clinical Congress in Austin, Texas. Dr. Caroline Messer (left), and Dr. Minisha Sood (right) discuss private practice, public health, and treatment preferences. Dr. Minisha Sood is an endocrinologist, assistant professor at …

Diabetes in Control Publisher Steve Freed talks with Dr. Karl Nadolsky at the AACE 26th Annual Scientific & Clinical Congress in Austin, Texas. Dr. Nadolsky discusses lifestyle as medicine and treating the disease of obesity in a holistic manner. Dr. Karl Nadolsky, DO is an endocrinologist at Walter Reed National …

This week we have an interesting article on the use of nonnutritive sweeteners.  Over the years, we have had many of these as one opinion or another had flip-flopped as to the benefit or harm of these products. As an educator, I have always been in favor of using them …